pregabalin indications/contra

Stem definitionDrug idCAS RN
gabamimetic agents 2255 148553-50-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pregabalin
  • (S)-Pregabalin
  • gabanext
  • maxgalin
  • lyrica
  • pregabalin hydrochloride
  • pregabalin HCl
A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.
  • Molecular weight: 159.23
  • Formula: C8H17NO2
  • CLOGP: -0.92
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 63.32
  • ALOGS: -1.15
  • ROTB: 5

Drug dosage:

DoseUnitRoute
0.30 g O

Approvals:

DateAgencyCompanyOrphan
July 6, 2004 EMA
Dec. 30, 2004 FDA PF PRISM CV

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pain 6182.04 25.10 2656 30046 68901 3284256
Weight increased 4956.35 25.10 1735 30967 25005 3328152
Somnolence 4810.94 25.10 1781 30921 30423 3322734
Dizziness 4170.46 25.10 2069 30633 74443 3278714
Drug ineffective 3294.61 25.10 2043 30659 114047 3239110
Oedema peripheral 2635.90 25.10 1181 31521 33180 3319977
Vision blurred 2547.02 25.10 982 31720 18607 3334550
Fall 2327.07 25.10 1289 31413 57594 3295563
Feeling abnormal 2325.04 25.10 1013 31689 26512 3326645
Drug hypersensitivity 2249.94 25.10 1071 31631 34609 3318548
Condition aggravated 2242.89 25.10 1101 31601 38132 3315025
Pain in extremity 1979.57 25.10 1091 31611 48121 3305036
Confusional state 1974.78 25.10 1000 31702 36998 3316159
Withdrawal syndrome 1899.11 25.10 546 32156 3848 3349309
Insomnia 1824.72 25.10 931 31771 34967 3318190
Gait disturbance 1749.45 25.10 836 31866 27156 3326001
Malaise 1621.18 25.10 1061 31641 64116 3289041
Tremor 1449.25 25.10 737 31965 27407 3325750
Drug abuse 1318.69 25.10 604 32098 17726 3335431
Hypoaesthesia 1300.79 25.10 659 32043 24280 3328877
Oedema 1294.41 25.10 558 32144 14122 3339035
Depression 1185.09 25.10 727 31975 39043 3314114
Memory impairment 1162.03 25.10 520 32182 14418 3338739
Suicidal ideation 1104.94 25.10 529 32173 17176 3335981
Drug effect incomplete 1101.62 25.10 417 32285 7433 3345724
Burning sensation 1082.14 25.10 426 32276 8478 3344679
Drug withdrawal syndrome 1032.01 25.10 446 32256 11339 3341818
Balance disorder 999.17 25.10 443 32259 11996 3341161
Intentional product misuse 990.31 25.10 443 32259 12258 3340899
Nausea 969.35 25.10 1054 31648 128591 3224566

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC N03AX16 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Other antiepileptics
CHEBI has role CHEBI:35623 anticonvulsant
MeSH PA D000700 Analgesics
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000927 Anticonvulsants
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018689 Sensory System Agents
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Postherpetic neuralgia indication 2177002
Generalized anxiety disorder indication 21897009 DOID:14320
Fibromyalgia indication 203082005 DOID:631
Diabetic peripheral neuropathy indication 424736006
Partial Epilepsy Treatment Adjunct indication
Suicidal thoughts contraindication 6471006
Weight gain finding contraindication 8943002
Reduced visual acuity contraindication 13164000
Depressive disorder contraindication 35489007 DOID:2848
Angioedema contraindication 41291007 DOID:1558
Chronic heart failure contraindication 48447003
Disorder of muscle contraindication 129565002 DOID:423
Decompensated cardiac failure contraindication 195111005
Impaired renal function disorder contraindication 197663003
Atrioventricular block contraindication 233917008 DOID:0050820
Rhabdomyolysis contraindication 240131006
Drowsy contraindication 271782001
Peripheral edema contraindication 271809000
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Dizziness contraindication 404640003

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.97 acidic
pKa2 10.4 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 MANAGEMENT OF FIBROMYALGIA
100MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 TREATMENT OF PAIN
100MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL RE41920 Dec. 30, 2018 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
150MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 MANAGEMENT OF FIBROMYALGIA
150MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 TREATMENT OF PAIN
150MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL RE41920 Dec. 30, 2018 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
200MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 MANAGEMENT OF FIBROMYALGIA
200MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 TREATMENT OF PAIN
200MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL RE41920 Dec. 30, 2018 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
225MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 MANAGEMENT OF FIBROMYALGIA
225MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 TREATMENT OF PAIN
225MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL RE41920 Dec. 30, 2018 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
25MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 MANAGEMENT OF FIBROMYALGIA
25MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 TREATMENT OF PAIN
25MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL RE41920 Dec. 30, 2018 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
300MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 MANAGEMENT OF FIBROMYALGIA
300MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 TREATMENT OF PAIN
300MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL RE41920 Dec. 30, 2018 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
50MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 MANAGEMENT OF FIBROMYALGIA
50MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 TREATMENT OF PAIN
50MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL RE41920 Dec. 30, 2018 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
75MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 MANAGEMENT OF FIBROMYALGIA
75MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL 6001876 Dec. 30, 2018 TREATMENT OF PAIN
75MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL RE41920 Dec. 30, 2018 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
20MG/ML LYRICA PF PRISM CV N022488 Jan. 4, 2010 RX SOLUTION ORAL 6001876 Dec. 30, 2018 MANAGEMENT OF FIBROMYALGIA
20MG/ML LYRICA PF PRISM CV N022488 Jan. 4, 2010 RX SOLUTION ORAL 6001876 Dec. 30, 2018 TREATMENT OF PAIN
20MG/ML LYRICA PF PRISM CV N022488 Jan. 4, 2010 RX SOLUTION ORAL RE41920 Dec. 30, 2018 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
165MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL RE41920 Dec. 30, 2018 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
165MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL RE41920 Dec. 30, 2018 TREATMENT OF POSTHERPETIC NEURALGIA
330MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL RE41920 Dec. 30, 2018 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
330MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL RE41920 Dec. 30, 2018 TREATMENT OF POSTHERPETIC NEURALGIA
82.5MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL RE41920 Dec. 30, 2018 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
82.5MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL RE41920 Dec. 30, 2018 TREATMENT OF POSTHERPETIC NEURALGIA
165MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL 8945620 Nov. 2, 2026 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
165MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL 8945620 Nov. 2, 2026 TREATMENT OF POSTHERPETIC NEURALGIA
330MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL 8945620 Nov. 2, 2026 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
330MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL 8945620 Nov. 2, 2026 TREATMENT OF POSTHERPETIC NEURALGIA
82.5MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL 8945620 Nov. 2, 2026 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
82.5MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL 8945620 Nov. 2, 2026 TREATMENT OF POSTHERPETIC NEURALGIA

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL Dec. 22, 2019 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
150MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL Dec. 22, 2019 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
200MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL Dec. 22, 2019 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
225MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL Dec. 22, 2019 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
25MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL Dec. 22, 2019 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
300MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL Dec. 22, 2019 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
50MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL Dec. 22, 2019 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
75MG LYRICA PF PRISM CV N021446 Dec. 30, 2004 RX CAPSULE ORAL Dec. 22, 2019 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
20MG/ML LYRICA PF PRISM CV N022488 Jan. 4, 2010 RX SOLUTION ORAL Dec. 22, 2019 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
165MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL Oct. 11, 2020 NEW PRODUCT
330MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL Oct. 11, 2020 NEW PRODUCT
82.5MG LYRICA CR PFIZER INC N209501 Oct. 11, 2017 RX TABLET, EXTENDED RELEASE ORAL Oct. 11, 2020 NEW PRODUCT

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent calcium channel subunit alpha-2/delta-1 Ion channel MODULATOR IC50 7.10 WOMBAT-PK CHEMBL
Voltage-dependent calcium channel subunit alpha-2/delta-2 Ion channel MODULATOR IC50 7.26 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Large neutral amino acids transporter small subunit 1 Transporter IC50 3.80 WOMBAT-PK
Uncharacterized protein; Voltage-dependent calcium channel alpha-2 delta subunit Ion channel IC50 7.14 CHEMBL

External reference:

scroll-->
IDSource
CHEBI:64356 CHEBI
DB00230 DRUGBANK_ID
4024924 VUID
N0000171595 NUI
C0657912 UMLSCUI
5484 IUPHAR_LIGAND_ID
D02716 KEGG_DRUG
55JG375S6M UNII
7643 INN_ID
415159003 SNOMEDCT_US
415160008 SNOMEDCT_US
19649 MMSL
d05508 MMSL
187832 RXNORM
4024924 VANDF
N0000023107 NDFRT
010083 NDDF
N0000171595 NDFRT
CHEMBL1059 ChEMBL_ID
D000069583 MESH_DESCRIPTOR_UI
5486971 PUBCHEM_CID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 0071-1012 CAPSULE 25 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 0071-1013 CAPSULE 50 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 0071-1014 CAPSULE 75 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 0071-1015 CAPSULE 100 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 0071-1016 CAPSULE 150 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 0071-1017 CAPSULE 200 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 0071-1018 CAPSULE 300 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 0071-1019 CAPSULE 225 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 0071-1020 SOLUTION 20 mg ORAL NDA 19 sections
Lyrica CR HUMAN PRESCRIPTION DRUG LABEL 1 0071-1026 TABLET, FILM COATED, EXTENDED RELEASE 82.50 mg ORAL NDA 19 sections
Lyrica CR HUMAN PRESCRIPTION DRUG LABEL 1 0071-1027 TABLET, FILM COATED, EXTENDED RELEASE 165 mg ORAL NDA 19 sections
Lyrica CR HUMAN PRESCRIPTION DRUG LABEL 1 0071-1029 TABLET, FILM COATED, EXTENDED RELEASE 330 mg ORAL NDA 19 sections
LYRICA HUMAN PRESCRIPTION DRUG LABEL 1 16590-503 CAPSULE 50 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 21695-276 CAPSULE 25 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 21695-277 CAPSULE 50 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 21695-278 CAPSULE 75 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 21695-661 CAPSULE 100 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 21695-662 CAPSULE 150 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 21695-663 CAPSULE 200 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 21695-664 CAPSULE 300 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 24236-783 CAPSULE 50 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 35356-053 CAPSULE 25 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 35356-054 CAPSULE 150 mg ORAL NDA authorized generic 25 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 35356-398 CAPSULE 300 mg ORAL NDA 11 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 42254-134 CAPSULE 225 mg ORAL NDA 18 sections
LYRICA HUMAN PRESCRIPTION DRUG LABEL 1 42549-612 CAPSULE 75 mg ORAL NDA 19 sections
LYRICA HUMAN PRESCRIPTION DRUG LABEL 1 42549-660 CAPSULE 50 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 43353-263 CAPSULE 50 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 43353-264 CAPSULE 75 mg ORAL NDA 19 sections
Lyrica HUMAN PRESCRIPTION DRUG LABEL 1 43353-413 CAPSULE 100 mg ORAL NDA 19 sections